These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

750 related items for PubMed ID: 17685465

  • 1. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.
    Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C.
    Cancer; 2007 Sep 15; 110(6):1218-26. PubMed ID: 17685465
    [Abstract] [Full Text] [Related]

  • 2. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
    Buitrago D, Keutgen XM, Crowley M, Filicori F, Aldailami H, Hoda R, Liu YF, Hoda RS, Scognamiglio T, Jin M, Fahey TJ, Zarnegar R.
    Ann Surg Oncol; 2012 Mar 15; 19(3):973-80. PubMed ID: 21879273
    [Abstract] [Full Text] [Related]

  • 3. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
    Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK.
    Clin Endocrinol (Oxf); 2006 Sep 15; 65(3):364-8. PubMed ID: 16918957
    [Abstract] [Full Text] [Related]

  • 4. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
    Erickson LA, Jin L, Nakamura N, Bridges AG, Markovic SN, Lloyd RV.
    Cancer; 2007 May 15; 109(10):1965-71. PubMed ID: 17387744
    [Abstract] [Full Text] [Related]

  • 5. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas.
    Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, Wada N, Rino Y, Masuda M, Imada T.
    Anticancer Res; 2007 May 15; 27(5B):3645-9. PubMed ID: 17972530
    [Abstract] [Full Text] [Related]

  • 6. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.
    Clin Endocrinol (Oxf); 2008 Apr 15; 68(4):618-34. PubMed ID: 18070147
    [Abstract] [Full Text] [Related]

  • 7. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
    Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, Zhang Y, Cheng W, Zhao W.
    Ann Surg Oncol; 2009 Feb 15; 16(2):240-5. PubMed ID: 19034577
    [Abstract] [Full Text] [Related]

  • 8. [Expression of BRAF V600E mutation in different thyroid lesions].
    Wang W, Li XH, Zhang YH, Li J, Chen J, Zhao P, Li QY, Xiang JJ, Li X, Xu RJ.
    Zhonghua Zhong Liu Za Zhi; 2011 May 15; 33(5):354-7. PubMed ID: 21875464
    [Abstract] [Full Text] [Related]

  • 9. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.
    Wang W, Zhao W, Wang H, Teng X, Wang H, Chen X, Li Z, Yu X, Fahey TJ, Teng L.
    Ann Surg Oncol; 2012 Jan 15; 19(1):31-6. PubMed ID: 22033631
    [Abstract] [Full Text] [Related]

  • 10. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
    Paulson L, Shindo M, Schuff K, Corless C.
    Arch Otolaryngol Head Neck Surg; 2012 Jan 15; 138(1):44-9. PubMed ID: 22249628
    [Abstract] [Full Text] [Related]

  • 11. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
    Rossi ED, Martini M, Capodimonti S, Lombardi CP, Pontecorvi A, Vellone VG, Zannoni GF, Larocca LM, Fadda G.
    Cancer Cytopathol; 2013 Jun 15; 121(6):291-7. PubMed ID: 23192956
    [Abstract] [Full Text] [Related]

  • 12. Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.
    Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, Nikiforova MN, Nikiforov YE, Yip L.
    Ann Surg Oncol; 2011 Dec 15; 18(13):3566-71. PubMed ID: 21594703
    [Abstract] [Full Text] [Related]

  • 13. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
    Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R.
    Endocr Relat Cancer; 2008 Mar 15; 15(1):191-205. PubMed ID: 18310287
    [Abstract] [Full Text] [Related]

  • 14. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
    Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R.
    Endocr Relat Cancer; 2006 Jun 15; 13(2):455-64. PubMed ID: 16728573
    [Abstract] [Full Text] [Related]

  • 15. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.
    Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, McCoy KL, Nikiforov YE, Yip L.
    Ann Surg Oncol; 2013 Jan 15; 20(1):47-52. PubMed ID: 22941165
    [Abstract] [Full Text] [Related]

  • 16. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR.
    Jeong D, Jeong Y, Park JH, Han SW, Kim SY, Kim YJ, Kim SJ, Hwangbo Y, Park S, Cho HD, Oh MH, Yang SH, Kim CJ.
    Ann Surg Oncol; 2013 Mar 15; 20(3):759-66. PubMed ID: 23179992
    [Abstract] [Full Text] [Related]

  • 17. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
    Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A.
    Acta Neuropathol; 2011 Jul 15; 122(1):11-9. PubMed ID: 21638088
    [Abstract] [Full Text] [Related]

  • 18. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis.
    Lee JH, Lee ES, Kim YS.
    Cancer; 2007 Jul 01; 110(1):38-46. PubMed ID: 17520704
    [Abstract] [Full Text] [Related]

  • 19. Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases.
    Zerilli M, Amato MC, Martorana A, Cabibi D, Coy JF, Cappello F, Pompei G, Russo A, Giordano C, Rodolico V.
    Cancer; 2008 Sep 01; 113(5):936-44. PubMed ID: 18615628
    [Abstract] [Full Text] [Related]

  • 20. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.
    Sheu SY, Grabellus F, Schwertheim S, Handke S, Worm K, Schmid KW.
    Horm Metab Res; 2009 Jun 01; 41(6):482-7. PubMed ID: 19370505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.